Zura Bio Limited (NASDAQ:ZURA - Get Free Report)'s share price traded down 1.6% during trading on Friday . The company traded as low as $1.22 and last traded at $1.26. 142,746 shares were traded during mid-day trading, a decline of 64% from the average session volume of 391,106 shares. The stock had previously closed at $1.28.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on ZURA shares. HC Wainwright reiterated a "neutral" rating and set a $5.00 target price on shares of Zura Bio in a research report on Tuesday, December 24th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zura Bio in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $15.80.
Get Our Latest Stock Analysis on Zura Bio
Zura Bio Stock Up 2.5 %
The company has a 50 day moving average of $1.71 and a 200 day moving average of $2.97.
Hedge Funds Weigh In On Zura Bio
Hedge funds and other institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. grew its stake in Zura Bio by 51.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company's stock valued at $1,185,000 after acquiring an additional 98,972 shares in the last quarter. Valence8 US LP purchased a new stake in shares of Zura Bio in the third quarter valued at approximately $71,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Zura Bio in the third quarter valued at approximately $71,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Zura Bio during the third quarter worth approximately $46,000. Finally, MetLife Investment Management LLC acquired a new position in Zura Bio during the third quarter worth $111,000. 61.14% of the stock is owned by hedge funds and other institutional investors.
About Zura Bio
(
Get Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Featured Stories
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
